Track all markets on TradingView
Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth
Media

Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth

  • November 13, 2024
  • 18 Views

Atai Life Sciences reports Q3 results, highlighting FDA clearance for DMT film, upcoming MDMA trials, and a strong cash position.

read more

​ 

​Atai Life Sciences reports Q3 results, highlighting FDA clearance for DMT film, upcoming MDMA trials, and a strong cash position.
read more 

Share This Post:

This material is for informational purposes is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. The opinions expressed are as of date of publication and are subject to change. Reliance upon information in this material is at the sole discretion of the reader. Past performance is not indicative of current or future results. This information provided is neither tax nor legal advice and investors should consult with their own advisors before making investment decisions. Investment involves risk including possible loss of principal.